MedTrace Logo

Efficacy and Safety Evaluation of BCMA-UCART

NCT03752541 · Status: SUSPENDED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-05-20

No results posted yet for this study

Summary

This trial aims to evaluate the safety and efficacy of BCMA-UCART in treating patients with relapsed or refractory multiple myeloma.

Conditions

Interventions

BIOLOGICAL

BCMA-UCART

A conditioning therapy with cyclophosphamide and fludarabine will be conducted for subjects before CART therapy.

Sponsors & Collaborators

  • Shanghai Tongji Hospital, Tongji University School of Medicine

    collaborator OTHER

  • Second Xiangya Hospital of Central South University

    collaborator OTHER

  • Bioray Laboratories

    lead INDUSTRY

Principal Investigators

  • Aibin Liang, PhD · Shanghai Tongji Hospital, Tongji University School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-11-01
Primary Completion
2023-03-20
Completion
2023-11-20

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03752541 on ClinicalTrials.gov